PIC Therapeutics, a preclinical stage biotech company focused on cancer therapies, has expanded its team with the hiring of a chief development officer.
The Natick firm has hired Richard Gedrich to its leadership team. Gedrich has 25 years of experience as an executive in preclinical, translational, and clinical research spanning aspects of drug discovery, according to a Thursday press release from PIC.
Gerich was previously executive director at Arvinas, a New Haven-based public clinical stage biotechnology company.
“PIC’s innovative approach to targeting dysregulated protein translation has tremendous potential to benefit patients with aggressive cancers in need of novel therapies. I am eager to work with the team and contribute my experience as PIC transitions into a clinical-stage company,” Gedrich said in the press release.
In October 2022, the Natick biopharma firm closed a $35 million financing round for research for drug-resistant breast cancer.
